Lucinactant
Names
[ CAS No. ]:
825600-90-6
[ Name ]:
Lucinactant
Biological Activity
[Description]:
Lucinactant is a novel synthetic peptide that functionally mimics surfactant protein B, a protein with anti-inflammatory properties. Lucinactant is a KL4-Surfactant, protects human airway epithelium from hyperoxia[1][2][3].
[Related Catalog]:
[In Vitro]
Lucinactant (140 μL; 24 h and 72 h) provides anti-inflammatory protection compared with an animal-derived surfactant and saline control over 72 h of moderate hyperoxia[1]. Lucinactant (140 μL; 24 h) reduces IL-8 and IL-6 secretion compared with normal saline in hyperoxic exposed Calu-3 monolayers[1]. Lucinactant (140 μL; 24 h) decreases swollen nuclei and intracellular vacuoles in Calu-3 cells after 24 and 72 h of hyperoxia[1]. Cell Viability Assay[1] Cell Line: Hyperoxic exposed Calu-3 monolayers Concentration: 140 μL Incubation Time: 72 hours Result: Demonstrated great cell viability and transepithelial resistance.
[In Vivo]
Lucinactant (175 mg total phospholipid/5.8 mL/kg; intratracheal medication; single dose) attenuates pulmonary inflammatory response, preserves lung structure, and improves physiologic outcomes in a preterm lamb model of respiratory distress syndrome (RDS)[2]. Animal Model: Preterm lambs (125-128 d gestation)[2] Dosage: 175 mg total phospholipid/kg (5.8 mL/kg) Administration: Intratracheal medication; assessed lung inflammation biomarkers and lung histology at termination Result: Attenuated lung and systemic inflammatory response, supported oxygenation at lower ventilatory requirements, and preserved lung structural integrity to a great degree.
[References]
Chemical & Physical Properties
No Any Chemical & Physical Properties